FDA clears Roche Cobas c 703, Cobas ISE Neo
May 2026—The Food and Drug Administration granted 510(k) clearance to Roche’s Cobas c 703 and Cobas ISE Neo analytical units.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
Diagnostic Medicine Consortium partners with Virchow
May 2026—The Diagnostic Medicine Consortium and Virchow Medical have formed a partnership aimed at expanding longitudinal, evidence-based cancer therapy to more patients.
Omnia Inventa introduces LNL300 for lymph node retrieval
May 2026—Omnia Inventa Medical has introduced the Lymph Node Locator 300, an FDA class I, 510(k)-exempt device designed to standardize lymph node retrieval from fatty tissue in oncologic specimens.
Streck launches MDx-Chex for respiratory low-plex testing
May 2026—Streck released MDx-Chex for RLP, a ready-to-use, full-process molecular quality control designed for respiratory low-plex assay verification.
FDA approves Grifols malaria blood screening assay
May 2026—The FDA has approved Grifols’ Procleix Plasmodium assay for screening blood donors for malaria.
Sarstedt awarded innovative technology contract
May 2026—Sarstedt’s Tempus1800 sample transport system was awarded a Vizient innovative technology contract.
Project Santa Fe Foundation partners with Vivica
May 2026—Clinical Lab 2.0, an initiative of Project Santa Fe Foundation, is partnering with Life Data Lab, developer of Vivica LabReports, a laboratory platform that enables clinical labs to identify potential gaps in patient care (per provider request).
FDA clears GI panels on QIAstat-Dx Rise
May 2026—The Food and Drug Administration has cleared the Qiagen QIAstat-Dx Gastrointestinal Panel 2 and QIAstat-Dx GI Panel 2 Mini B and Mini B&V for use on the QIAstat-Dx Rise automated syndromic testing system.
Bruker launches MyGenius Pro MDx system
May 2026—Bruker’s microbiology and infection diagnostics division launched at ESCMID Global (April 17–21, Munich) the MyGenius Pro system in Europe.
In brain tumors, new use for CSF cfDNA
April 2026—It’s hard to mount an argument against the Great Plains. Nor is there much reason to. But drive across eastern Colorado, Nebraska, Kansas, or the Dakotas, and it is a bona fide thrill to arrive in Wyoming’s northwest corner and see the Grand Tetons rising up in spectacular fashion.